Jan Tack1, Jaakko Lappalainen2, Ulysses Diva3, Raj Tummala3, Mark Sostek3. 1. Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium. 2. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; currently at University of Pennsylvania, Philadelphia, PA, USA. 3. AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA.
Abstract
BACKGROUND: Treatment options for patients with opioid-induced constipation (OIC) and inadequate response to laxatives (LIR) are few. OBJECTIVE: Assess the efficacy and safety of orally administered naloxegol in patients with prospectively confirmed OIC and LIR. METHODS: We analyzed pooled data from two identical randomized, double-blind, placebo-controlled, Phase 3 trials of naloxegol in patients with non-cancer pain, OIC and LIR in which naloxegol (12.5 mg, n = 240; 25 mg, n = 241) or placebo (n = 239) were administered daily. We assessed the response rates, time to first post-dose laxation, spontaneous bowel movements (SBMs), OIC symptoms and patient-reported outcomes over 12 weeks. RESULTS:OIC response rates for the naloxegol 25-mg (p < 0.001) and the 12.5-mg (p = 0.005) LIR dose groups were higher than placebo. Median times to first post-dose SBM were 7.6, 19.2 and 41.1 hours for the naloxegol 25 mg, naloxegol 12.5 mg and placebo groups, respectively. Other SBM measures, daily symptoms of OIC, and both the Patient Assessment of Constipation - Symptoms and Patient Assessment of Constipation-Quality of Life scores improved from baseline with naloxegol treatment. Changes from baseline in opioid dose, pain scores and opioid withdrawal scores were similar among treatment groups. CONCLUSIONS:Naloxegol was efficacious, generally safe and well tolerated in the patients with OIC and LIR, while preserving opioid analgesia. ClinicalTrials.gov identifiers: NCT01309841; NCT01323790.
RCT Entities:
BACKGROUND: Treatment options for patients with opioid-induced constipation (OIC) and inadequate response to laxatives (LIR) are few. OBJECTIVE: Assess the efficacy and safety of orally administered naloxegol in patients with prospectively confirmed OIC and LIR. METHODS: We analyzed pooled data from two identical randomized, double-blind, placebo-controlled, Phase 3 trials of naloxegol in patients with non-cancer pain, OIC and LIR in which naloxegol (12.5 mg, n = 240; 25 mg, n = 241) or placebo (n = 239) were administered daily. We assessed the response rates, time to first post-dose laxation, spontaneous bowel movements (SBMs), OIC symptoms and patient-reported outcomes over 12 weeks. RESULTS:OIC response rates for the naloxegol 25-mg (p < 0.001) and the 12.5-mg (p = 0.005) LIR dose groups were higher than placebo. Median times to first post-dose SBM were 7.6, 19.2 and 41.1 hours for the naloxegol 25 mg, naloxegol 12.5 mg and placebo groups, respectively. Other SBM measures, daily symptoms of OIC, and both the Patient Assessment of Constipation - Symptoms and Patient Assessment of Constipation-Quality of Life scores improved from baseline with naloxegol treatment. Changes from baseline in opioid dose, pain scores and opioid withdrawal scores were similar among treatment groups. CONCLUSIONS:Naloxegol was efficacious, generally safe and well tolerated in the patients with OIC and LIR, while preserving opioid analgesia. ClinicalTrials.gov identifiers: NCT01309841; NCT01323790.
Entities:
Keywords:
Laxative-inadequate responder; naloxegol; opioid receptor antagonist; opioid-induced constipation; quality of life
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Jay Thomas; Sloan Karver; Gail Austin Cooney; Bruce H Chamberlain; Charles Kevin Watt; Neal E Slatkin; Nancy Stambler; Alton B Kremer; Robert J Israel Journal: N Engl J Med Date: 2008-05-29 Impact factor: 91.245
Authors: M Camilleri; D A Drossman; G Becker; L R Webster; A N Davies; G M Mawe Journal: Neurogastroenterol Motil Date: 2014-08-28 Impact factor: 3.598
Authors: Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo Journal: Curr Treat Options Oncol Date: 2021-02-26
Authors: Joseph V Pergolizzi; Robert B Raffa; Marco Pappagallo; Charles Fleischer; Joseph Pergolizzi; Gianpietro Zampogna; Elizabeth Duval; Janan Hishmeh; Jo Ann LeQuang; Robert Taylor Journal: Patient Prefer Adherence Date: 2017-01-17 Impact factor: 2.711